GNI Group invest to Micren Healthcare
and form a joint venture with EPS Group

GNI Group Ltd. (Chuo-ku, Tokyo; Director, Representative Executive Officer, President and CEO: Ying Luo) and EPS Holdings Inc. (Shinjuku-ku, Tokyo; Representative Director: Hao Yan; hereinafter “EPSHD”) has signed an agreement to acquire 60% of the outstanding shares of Micren Healthcare Co., Ltd. (Headquarters: Shinjuku-ku, Tokyo; President and Representative Director: Michiharu Miyahara; “Micren Healthcare”) with EPSHD’s subsidiary, EP Mediate Co., Ltd. (Headquarters: Shinjuku-ku, Tokyo; President and Representative Director: Masanori Tanji; “EP Mediate”), who currently owns Micren Healthcare, and formed as a joint venture.

Micren Healthcare holds a Type I Medical Device Marketing Authorization Holder license and provides professional and independent Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) for clinical trial services for medical devices. Micren Healthcare have handled novel medical devices, e.g., genetic testing sytem, SaMD with AI and deep learning technology which most often require clinical data in support of obtaining device approvals in Japan and have seen increase of foreign prospective clients.

Medical device industry in the world is expected to expand in the future, especially in China and Asian market. Forming Micren Healthcare as a joint venture, it is a small but first significant step for GNI to establish an operating presence in Japan and we will strengthen the support system for introducing foreign medical device in Japan market with GNI’s strong presence in the US and China.

—————————————————————————————————–
About GNI Group, Inc.:
GNI Group is a global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit GNI Group’s website below:
https://www.gnipharma.com/

About EPS Group:
The EPS Group is a healthcare solutions provider that has been handling all processes from drug discovery and development to sales, marketing, consulting, and various other solutions since its founding as a pioneer CRO in Japan in 1991. The Group broadening its businesses as well by also engaging in initiatives to bring new value to pharmaceutical and medical device companies, hospitals, clinics, and academia through efforts that include expansion in China and the rest of Asia, big data and AI, and regenerative medicine. In 2021, the EPS Holdings launched an innovative medicine business and started services to support the clinical development of seeds originating at academic institutions and domestic and global biotech ventures and to support marketing in and
outside Japan. For more information, please visit EPS Holdings’ website below:
https://www.eps-holdings.co.jp/en/

About EP Mediate:
As a CRO, EP Mediate provides services such as clinical research and clinical trials, post-marketing clinical trials, and regulatory consulting, mainly to Japanese medical device manufacturers and subsidiaries of foreign medical device manufacturers in Japan. For more information, please visit EP Mediate’s website below:
www.ep-mediate.co.jp

About Micren Healthcare:
Micren Healthcare holds a Type 1 Medical Device Marketing License and provides professional and independent Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services for medical devices.　For more information, please visit Micren Healthcare’s website below:
www.micren.co.jp